BridgeBio's $933.9 Million Preferred Stock Widens Its Common Loss By $26.3 Million
The 7% preferred lifted the loss per common share to $0.42 as a $550 million convertible note moved into current liabilities.
BridgeBio Pharma, which develops medicines for genetic diseases, said in its third-quarter 10-Q that dividends and accretion on the $933.9 million of preferred stock it sold on July 1 added $26.3 million to its loss. The charge took the net loss attributable to BridgeBio of $56.7 million to $83.0 million for common shareholders, or $0.42 a share.
How the preferred stock hits the common
Sixth Street and HealthCare Royalty affiliates bought 933,900 shares at $1,000 each. The stock pays a 7.00% dividend, accrues it daily whether or not declared, and ranks ahead of the common.
Of the $26.3 million recognized, $9.9 million is accretion of a discount booked because the dividend rate steps up over time. The filing amortizes that discount over an expected six-year life at an 11.17% effective rate, against the 7.00% coupon.
The preferred is left out of the loss-per-share calculation, but its cumulative dividends still enlarge the loss attributable to common holders. Its claim on liquidation has grown to $1,134,359 thousand, roughly $1.13 billion, as of September 30, versus $933.9 million originally invested.
BridgeBio has paid every dividend in cash so far, so no unpaid dividends have compounded. Had it chosen to pay in kind, they would compound into the amount owed. The company early adopted a new accounting standard, ASU 2026-01, on July 1, 2026, which it said changed nothing but disclosures.
Conversion price sits far above the buyback price
The preferred converts at $137.79 a share, rising to $153.10 on the fifth anniversary of issuance. Under a repurchase program of up to $500.0 million, the company bought 2,616,166 common shares at an average $66.88 by September 30, for about $175.0 million.
The company expects to convert the stock or redeem it before the seventh anniversary, when the dividend rate steps up.
A $550 million note comes due
The 2.50% convertible notes due March 15, 2027, carried at $548.4 million, are now a current liability. Holders can convert them from October 1 through December 14, 2026, and again at any time from December 15, because a stock-price condition was met.
BridgeBio plans to use proceeds from its 2033 notes to settle conversions or repay part of the 2027 notes. It held $1.5 billion in cash and marketable securities at quarter end and expects that to fund operations for at least 12 months.
The business behind the numbers is growing. Revenue was $353.2 million in the quarter, including a $75.0 million Bayer sales milestone, and the loss from operations narrowed to $11.6 million. Its heart drug Attruby brought in $253.3 million in net product revenue.
The FDA's target decision date for BBP-418, the company's muscular dystrophy candidate, is November 27, 2026, and the 2027 notes mature on March 15, 2027.
Sources
- 10-Q Filing — BridgeBio Pharma (BBIO) — SEC EDGAR
- 10-Q Filing — BridgeBio Pharma (BBIO), Q2 FY2026 filed 2026-08-10 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, bbio-20260930xex991.htm) — BridgeBio Pharma, filed 2026-10-29 — SEC EDGAR
- BridgeBio Pharma GAAP EPS of -$0.42 beats by $0.17, revenue of $353.17M beats by $57.42M (NASDAQ:BBIO) | Seeking Alpha — seekingalpha.com
- BridgeBio Pharma: Q3 Earnings Snapshot – WTOP News — wtop.com
- BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates — Yahoo Finance
- BridgeBio Reports Third Quarter 2026 Financial Results and — globenewswire.com